No statistically significant differences were observed between the COMBO group and the STAN group regarding other adverse events, including CDI (RR = 1.80, 95% CI: 0.91–3.57, p=0.09; I2 = 0%) (Figure 13(a)), CPK elevation (RR = 1.1, 95% CI: 0.43–2.81, p=0.84; I2 = 0%) (Figure 13(b)), and thrombocytopenia (RR = 1.22, 95% CI: 0.79–1.88, p=0.37; I2 = 0%) (Figure 13(c)). The gene discussed is PIK3C2A; the disease is Thrombocytopenia.